Back to Search

Afimkibart for Moderate to Severe Rheumatoid Arthritis

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

Recruiting Phase 2 Interventional Study
Rheumatoid Arthritis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
120 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Who this trial is looking for

This trial is looking for people with moderate to severe rheumatoid arthritis who haven't responded well to certain previous treatments. Participants will have previously taken Afimkibart and will be monitored for their health over time.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have completed the treatment period of the parent study.
  • I agree to follow contraception requirements.
  • I achieved improvement in my joint evaluation compared to before.

You may not be able to join if

  • I withdrew my consent or stopped participating in the parent study.
  • I permanently stopped taking the study drug in the parent study.
  • I used a therapy not allowed during the parent study.
  • I have a new or uncontrolled health condition that prevents me from participating.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Completed the treatment period of the parent study * Agreement to adhere to the contraception requirements * Continued to be evaluated at the follow-up visit of the parent study and achieved improvement in the SJC66/TJC68 relative to baseline Exclusion Criteria: * Withdrawal…
Contacts

Reference Study ID Number: WA46440 https://forpatients.roche.com/ No attachments to email below.

888-662-6728

global-roche-genentech-trials@gene.com

CONTACT

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

NCT ID: NCT07620392 Source: ClinicalTrials.gov